Back to Journals » Therapeutics and Clinical Risk Management » Volume 9
Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
Received 26 June 2013
Accepted for publication 6 September 2013
Published 25 October 2013 Volume 2013:9 Pages 403—408
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Sedat Yilmaz, Ismail Simsek
Division of Rheumatology, Gulhane School of Medicine, Ankara, Turkey
Abstract: Tocilizumab is a fully humanized monoclonal antibody against interleukin-6 receptors that was approved for the treatment of patients with rheumatoid arthritis (RA). Several lines of evidence, obtained both from conventional disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor (TNF) inhibitors, have supported the concept of "window of opportunity" as showing that these therapies consistently work better in early disease as compared to established RA. This review addresses the question of whether a window of opportunity gained with conventional DMARDs and TNF inhibitors can also be achieved with tocilizumab. To this end, data regarding the use of tocilizumab in early RA patients are summarized. Currently available data suggest that the earlier the treatment with tocilizumab, the better the clinical outcome can be, which may have implications for various aspects of RA treatment strategies.
Keywords: rheumatoid arthritis, tocilizumab, early intervention
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.